MONTE ROSA THERAPEUTICS INC (GLUE) Stock Fundamental Analysis
USA - NASDAQ:GLUE - US61225M1027 - Common Stock
12.31 USD
-0.7 (-5.38%)
12.2905 USD
-0.02 (-0.16%)
Taking everything into account, GLUE scores 5 out of 10 in our fundamental rating. GLUE was compared to 531 industry peers in the Biotechnology industry. GLUE has an excellent financial health rating, but there are some minor concerns on its profitability. GLUE is valued correctly, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
GLUE had positive earnings in the past year.
GLUE had a positive operating cash flow in the past year.
GLUE had negative earnings in each of the past 5 years.
GLUE had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
GLUE's Return On Assets of 6.72% is amongst the best of the industry. GLUE outperforms 92.16% of its industry peers.
GLUE has a Return On Equity of 9.02%. This is amongst the best in the industry. GLUE outperforms 93.28% of its industry peers.
GLUE has a better Return On Invested Capital (3.72%) than 91.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.72% | ||
| ROE | 9.02% | ||
| ROIC | 3.72% |
ROA(3y)-30.94%
ROA(5y)-37.13%
ROE(3y)-49.37%
ROE(5y)-71.64%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of GLUE (13.58%) is better than 93.28% of its industry peers.
With an excellent Operating Margin value of 8.40%, GLUE belongs to the best of the industry, outperforming 91.60% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.4% | ||
| PM (TTM) | 13.58% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so GLUE is destroying value.
Compared to 1 year ago, GLUE has more shares outstanding
GLUE has more shares outstanding than it did 5 years ago.
GLUE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
GLUE has an Altman-Z score of 4.90. This indicates that GLUE is financially healthy and has little risk of bankruptcy at the moment.
GLUE has a Altman-Z score of 4.90. This is in the better half of the industry: GLUE outperforms 74.81% of its industry peers.
GLUE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 4.9 |
ROIC/WACC0.43
WACC8.75%
2.3 Liquidity
GLUE has a Current Ratio of 7.16. This indicates that GLUE is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of GLUE (7.16) is better than 70.15% of its industry peers.
A Quick Ratio of 7.16 indicates that GLUE has no problem at all paying its short term obligations.
GLUE has a better Quick ratio (7.16) than 70.52% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.16 | ||
| Quick Ratio | 7.16 |
3. Growth
3.1 Past
GLUE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 116.94%, which is quite impressive.
EPS 1Y (TTM)116.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.79%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%38.54%
3.2 Future
Based on estimates for the next years, GLUE will show a decrease in Earnings Per Share. The EPS will decrease by -6.65% on average per year.
The Revenue is expected to grow by 22.64% on average over the next years. This is a very strong growth
EPS Next Y68.04%
EPS Next 2Y-17.4%
EPS Next 3Y-7.39%
EPS Next 5Y-6.65%
Revenue Next Year382.42%
Revenue Next 2Y40.02%
Revenue Next 3Y36.35%
Revenue Next 5Y22.64%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 39.71 indicates a quite expensive valuation of GLUE.
GLUE's Price/Earnings ratio is rather cheap when compared to the industry. GLUE is cheaper than 91.98% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.06. GLUE is valued rather expensively when compared to this.
The Forward Price/Earnings Ratio is negative for GLUE. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 39.71 | ||
| Fwd PE | N/A |
4.2 Price Multiples
GLUE's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. GLUE is cheaper than 96.46% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, GLUE is valued cheaply inside the industry as 93.28% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 31.87 | ||
| EV/EBITDA | 10.67 |
4.3 Compensation for Growth
GLUE's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
GLUE's earnings are expected to decrease with -7.39% in the coming years. This may justify a cheaper valuation.
PEG (NY)0.58
PEG (5Y)N/A
EPS Next 2Y-17.4%
EPS Next 3Y-7.39%
5. Dividend
5.1 Amount
GLUE does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
12.31
-0.7 (-5.38%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners100.28%
Inst Owner Change-0.41%
Ins Owners0.85%
Ins Owner Change-0.02%
Market Cap760.27M
Revenue(TTM)75.62M
Net Income(TTM)24.17M
Analysts84
Price Target17.05 (38.51%)
Short Float %13.2%
Short Ratio5.44
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)162.39%
Min EPS beat(2)61.87%
Max EPS beat(2)262.91%
EPS beat(4)4
Avg EPS beat(4)361.68%
Min EPS beat(4)41.55%
Max EPS beat(4)1080.39%
EPS beat(8)7
Avg EPS beat(8)176.66%
EPS beat(12)11
Avg EPS beat(12)118.84%
EPS beat(16)13
Avg EPS beat(16)84.29%
Revenue beat(2)2
Avg Revenue beat(2)277.73%
Min Revenue beat(2)110.55%
Max Revenue beat(2)444.91%
Revenue beat(4)4
Avg Revenue beat(4)305.64%
Min Revenue beat(4)110.55%
Max Revenue beat(4)444.91%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)2.63%
EPS NQ rev (1m)-2.85%
EPS NQ rev (3m)4.08%
EPS NY rev (1m)-65.6%
EPS NY rev (3m)43.22%
Revenue NQ rev (1m)-13.72%
Revenue NQ rev (3m)-48.46%
Revenue NY rev (1m)-6.02%
Revenue NY rev (3m)12.02%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 39.71 | ||
| Fwd PE | N/A | ||
| P/S | 4.27 | ||
| P/FCF | 31.87 | ||
| P/OCF | 27.43 | ||
| P/B | 2.84 | ||
| P/tB | 2.84 | ||
| EV/EBITDA | 10.67 |
EPS(TTM)0.31
EY2.52%
EPS(NY)-1.41
Fwd EYN/A
FCF(TTM)0.39
FCFY3.14%
OCF(TTM)0.45
OCFY3.65%
SpS2.88
BVpS4.34
TBVpS4.34
PEG (NY)0.58
PEG (5Y)N/A
Graham Number5.5
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.72% | ||
| ROE | 9.02% | ||
| ROCE | 4.71% | ||
| ROIC | 3.72% | ||
| ROICexc | 43.54% | ||
| ROICexgc | 43.54% | ||
| OM | 8.4% | ||
| PM (TTM) | 13.58% | ||
| GM | N/A | ||
| FCFM | 13.4% |
ROA(3y)-30.94%
ROA(5y)-37.13%
ROE(3y)-49.37%
ROE(5y)-71.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.49
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 46.35% | ||
| Cap/Sales | 2.17% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 118.97% | ||
| Profit Quality | 98.69% | ||
| Current Ratio | 7.16 | ||
| Quick Ratio | 7.16 | ||
| Altman-Z | 4.9 |
F-Score8
WACC8.75%
ROIC/WACC0.43
Cap/Depr(3y)233.13%
Cap/Depr(5y)356.8%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)116.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.79%
EPS Next Y68.04%
EPS Next 2Y-17.4%
EPS Next 3Y-7.39%
EPS Next 5Y-6.65%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%38.54%
Revenue Next Year382.42%
Revenue Next 2Y40.02%
Revenue Next 3Y36.35%
Revenue Next 5Y22.64%
EBIT growth 1Y110.73%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year98.33%
EBIT Next 3Y21.23%
EBIT Next 5YN/A
FCF growth 1Y120.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y129.71%
OCF growth 3YN/A
OCF growth 5YN/A
MONTE ROSA THERAPEUTICS INC / GLUE FAQ
Can you provide the ChartMill fundamental rating for MONTE ROSA THERAPEUTICS INC?
ChartMill assigns a fundamental rating of 5 / 10 to GLUE.
Can you provide the valuation status for MONTE ROSA THERAPEUTICS INC?
ChartMill assigns a valuation rating of 4 / 10 to MONTE ROSA THERAPEUTICS INC (GLUE). This can be considered as Fairly Valued.
What is the profitability of GLUE stock?
MONTE ROSA THERAPEUTICS INC (GLUE) has a profitability rating of 4 / 10.
What is the earnings growth outlook for MONTE ROSA THERAPEUTICS INC?
The Earnings per Share (EPS) of MONTE ROSA THERAPEUTICS INC (GLUE) is expected to grow by 68.04% in the next year.